About Rigel Pharmaceuticals (NASDAQ:RIGL)
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100
Debt
Debt-to-Equity RatioN/A
Current Ratio6.41%
Quick Ratio6.41%
Price-To-Earnings
Trailing P/E Ratio-6.71
Forward P/E Ratio-5.97
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.48 million
Price / Sales133.55
Cash FlowN/A
Price / CashN/A
Book Value$0.69 per share
Price / Book5.88
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-77,990,000.00
Net MarginsN/A
Return on Equity-100.48%
Return on Assets-82.72%
Miscellaneous
Employees103
Outstanding Shares147,370,000
Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions
What is Rigel Pharmaceuticals' stock symbol?
Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."
How were Rigel Pharmaceuticals' earnings last quarter?
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.05. During the same quarter in the prior year, the company posted ($0.16) EPS. View Rigel Pharmaceuticals' Earnings History.
When is Rigel Pharmaceuticals' next earnings date?
What price target have analysts set for RIGL?
5 Wall Street analysts have issued 12-month price objectives for Rigel Pharmaceuticals' shares. Their forecasts range from $6.00 to $8.00. On average, they expect Rigel Pharmaceuticals' share price to reach $7.20 in the next twelve months. View Analyst Ratings for Rigel Pharmaceuticals.
What are Wall Street analysts saying about Rigel Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "Premature to Write-off IgAN for Now. Given the totality of the data and unmet need in IgAN, we have slightly lowered our probability of success for the program. While the data did not meet the primary endpoint of a statistically significant mean change in proteinuria from baseline, several positive trends were found among a pre-specified population of patients with greater than 1,000mg/g of proteinuria. Treatment with 150mg fostamatinib twice daily at 24-weeks led to a median reduction in proteinuria from baseline of 803mg/ g (n=15), compared with 100mg fostamatinib’s reduction of 720mg/g (n=16) and placebo’s reduction of 177mg/g (n=14). These trends were also observed among patients who entered the study with a baseline proteinuria of 2,000mg/g. During the study safety events were in-line with previous experiences, with two patients experiencing severe adverse events across each cohort and two events reported as drug related (pancreatitis and abnormal liver enzyme). As a reminder, fostamatinib has over 5,000 patient-years of experience generated with the drug. Going forward, Rigel plans to advance the IgAN program through collaborations with a pharmaceutical partner, which we believe could be potentially bundled with an ex-U.S. territory licensing of TAVLISSE for lead indication ITP." (4/3/2018)
- 2. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (3/10/2018)
Who are some of Rigel Pharmaceuticals' key competitors?
Some companies that are related to Rigel Pharmaceuticals include Revance Therapeutics (RVNC), Mallinckrodt (MNK), WAVE Life Sciences (WVE), Epizyme (EPZM), Intra-Cellular Therapies (ITCI), Athenex (ATNX), Retrophin (RTRX), Zai Lab (ZLAB), TG Therapeutics (TGTX), CytomX Therapeutics (CTMX), MacroGenics (MGNX), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Assembly Biosciences (ASMB), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Mirati Therapeutics (MRTX) and Amarin (AMRN).
Who are Rigel Pharmaceuticals' key executives?
Rigel Pharmaceuticals' management team includes the folowing people:
- Mr. Raul R. Rodriguez, CEO, Pres & Director (Age 57)
- Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53)
- Dr. Anne-Marie S. Duliege M.D., M.S., Chief Medical Officer and Exec. VP (Age 59)
- Mr. Eldon C. Mayer III, Chief Commercial Officer and Exec. VP (Age 57)
- Dr. Thomas A. Raffin, Co-Founder (Age 71)
Has Rigel Pharmaceuticals been receiving favorable news coverage?
Media coverage about RIGL stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rigel Pharmaceuticals earned a news sentiment score of 0.07 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.82 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Rigel Pharmaceuticals?
Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rigel Pharmaceuticals' stock price today?
One share of RIGL stock can currently be purchased for approximately $4.06.
How big of a company is Rigel Pharmaceuticals?
Rigel Pharmaceuticals has a market capitalization of $605.69 million and generates $4.48 million in revenue each year. The biotechnology company earns $-77,990,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Rigel Pharmaceuticals employs 103 workers across the globe.
How can I contact Rigel Pharmaceuticals?
Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]
MarketBeat Community Rating for Rigel Pharmaceuticals (RIGL)
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Rigel Pharmaceuticals in the last 12 months. Their average twelve-month price target is $7.20, suggesting that the stock has a possible upside of 77.34%. The high price target for RIGL is $8.00 and the low price target for RIGL is $6.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.20 | $6.00 | $5.80 | $6.75 |
| Price Target Upside: | 77.34% upside | 42.52% upside | 41.81% upside | 108.98% upside |
Rigel Pharmaceuticals (NASDAQ:RIGL) Consensus Price Target History
Rigel Pharmaceuticals (NASDAQ:RIGL) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Rigel Pharmaceuticals (NASDAQ:RIGL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.38%
Institutional Ownership Percentage: 92.33%
Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/3/2017 | Ryan D Maynard | CFO | Sell | 100,000 | $3.90 | $390,000.00 | 100,000 |  |
| 7/5/2017 | Anne-Marie Duliege | Insider | Sell | 5,000 | $2.69 | $13,450.00 | | |
| 8/30/2016 | Donald G Payan | EVP | Sell | 5,303 | $4.00 | $21,212.00 | | |
| 4/1/2015 | Donald G Payan | EVP | Sell | 10,000 | $3.75 | $37,500.00 | | |
| 12/18/2014 | Dolly Vance | EVP | Sell | 1,000 | $2.22 | $2,220.00 | | |
| 9/3/2014 | Donald G Payan | EVP | Sell | 20,000 | $2.56 | $51,200.00 | | |
| 11/19/2013 | Bvf Partners P/Il | major shareholder | Sell | 484,622 | $2.64 | $1,279,402.08 | | |
| 6/7/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 32,700 | $3.47 | $113,469.00 | | |
| 9/13/2012 | Dolly Vance | EVP | Sell | 4,151 | $10.43 | $43,294.93 | | |
(Data available from 1/1/2013 forward)
Rigel Pharmaceuticals (NASDAQ RIGL) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Rigel Pharma (RIGL) Reports FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia
www.streetinsider.com - April 19 at 9:26 AM |
 | 2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities
www.bizjournals.com - April 18 at 4:46 PM |
| Rigel Pharmaceuticals (RIGL) PT Raised to $8 at BMO Capital on FDA Approval
www.streetinsider.com - April 18 at 4:46 PM |
 | Analysts See 100% Upside To Rigel After Tavalisse Approval
finance.yahoo.com - April 18 at 4:45 PM |
| 2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities
finance.yahoo.com - April 18 at 4:45 PM |
| Rigel Announces Proposed Public Offering Of Common Stock
finance.yahoo.com - April 18 at 4:45 PM |
 | BMO Capital Markets Boosts Rigel Pharmaceuticals (RIGL) Price Target to $8.00
www.americanbankingnews.com - April 18 at 11:17 AM |
| Jefferies Group Boosts Rigel Pharmaceuticals (RIGL) Price Target to $7.00
www.americanbankingnews.com - April 18 at 9:46 AM |
 | Rigel : FDA Okays TAVALISSE For Chronic Immune Thrombocytopenia In Adult
www.nasdaq.com - April 18 at 9:26 AM |
| Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
www.bizjournals.com - April 18 at 9:26 AM |
 | Rigel Overcomes Its First FDA Approval Barrier, Is There More To Come?
seekingalpha.com - April 18 at 9:26 AM |
| Rigel Pharmaceuticals (RIGL) Price Target Raised to $8.00
www.americanbankingnews.com - April 18 at 9:00 AM |
| Rigel Pharmaceuticals (RIGL) PT Set at $6.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 18 at 8:37 AM |
| Piper Jaffray Increases Rigel Pharmaceuticals (RIGL) Price Target to $7.00
www.americanbankingnews.com - April 17 at 9:20 PM |
| Trading in Rigel halted ahead of expected FDA OK for Tavalisse for immune thrombocytopenia; shares up 10%
seekingalpha.com - April 17 at 4:55 PM |
| Here's Why Rigel Pharmaceuticals Rose as Much as 10.2% Today
finance.yahoo.com - April 17 at 4:55 PM |
| FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder
finance.yahoo.com - April 17 at 4:55 PM |
| Here's Why Rigel Pharmaceuticals Rose as Much as 10.2% Today
finance.yahoo.com - April 17 at 4:55 PM |
| Here’s What Happened Last Week In Biotech
finance.yahoo.com - April 17 at 9:47 AM |
| The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound
finance.yahoo.com - April 16 at 4:27 PM |
| Rigel Pharmaceuticals, Inc. (RIGL) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 15 at 11:29 AM |
| Rigel Pharmaceuticals (RIGL) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 15 at 10:59 AM |
| Rigel Pharma (RIGL) April option implied volatility elevated into FDA action date
www.streetinsider.com - April 13 at 4:31 PM |
 | Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why
www.zacks.com - April 13 at 4:31 PM |
| When Biotech Gets Even Riskier
finance.yahoo.com - April 13 at 4:31 PM |
| Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why
finance.yahoo.com - April 13 at 4:31 PM |
 | Here's What Caused Rigel Pharmaceuticals' Wild Ride Today
www.msn.com - April 13 at 9:49 AM |
 | News that made Rigel stock pop was a mistake, Rigel says
www.marketwatch.com - April 13 at 9:49 AM |
| Wild ride for Rigel Pharmaceuticals
seekingalpha.com - April 12 at 4:28 PM |
| Rigel Makes Statement Regarding Website Error
finance.yahoo.com - April 12 at 4:28 PM |
| Rigel Pharmaceuticals (RIGL) Given Buy Rating at Jefferies Group
www.americanbankingnews.com - April 9 at 1:19 PM |
| Rigel Fumbles A Phase 2, Can Stage A Potential Comeback With FDA Approval
seekingalpha.com - April 9 at 9:39 AM |
| BMO Capital Markets Reiterates Buy Rating for Rigel Pharmaceuticals (RIGL)
www.americanbankingnews.com - April 8 at 10:49 AM |
| Rigel Pharmaceuticals (RIGL) Raised to Sell at ValuEngine
www.americanbankingnews.com - April 8 at 10:46 AM |
| Why Rigel Is Worth A Look Despite Failed Study In IgAN
seekingalpha.com - April 6 at 4:42 PM |
| Rigel Pharma (RIGL) Says Phase 2 Study of Fostamatinib in IgA Did Not Achieve Statistical Significance for its Primary Endpoint
www.streetinsider.com - April 5 at 9:05 AM |
| Rigel Pharmaceuticals To Test The FDA
seekingalpha.com - April 5 at 9:05 AM |
| Rigel Pharmaceuticals, Inc. Expected to Earn Q3 2018 Earnings of ($0.15) Per Share (RIGL)
www.americanbankingnews.com - April 5 at 7:54 AM |
| Rigel Pharmaceuticals (RIGL) Updates on Fostamatinib Phase 2 In IgAN Top Line Results - Slideshow
seekingalpha.com - April 4 at 5:00 PM |
| Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug
finance.yahoo.com - April 4 at 5:00 PM |
| Zacks: Brokerages Expect Rigel Pharmaceuticals, Inc. (RIGL) to Announce -$0.17 EPS
www.americanbankingnews.com - April 3 at 7:12 PM |
| Pre-Open Movers 04/03: (MGI) (TSLA) (X) Higher; (LFIN) (SWCH) (RIGL) Lower (more...)
www.streetinsider.com - April 3 at 4:32 PM |
| Here's Why Rigel Pharmaceuticals Inc. Stock Is Slipping Today
www.msn.com - April 3 at 4:32 PM |
| Here's Why Rigel Pharmaceuticals Inc. Stock Is Slipping Today
finance.yahoo.com - April 3 at 4:32 PM |
| HC Wainwright Reiterates $7.00 Price Target for Rigel Pharmaceuticals (RIGL)
www.americanbankingnews.com - April 3 at 3:35 PM |
| Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy
finance.yahoo.com - April 3 at 9:44 AM |
| Rigel Pharmaceuticals (RIGL) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - March 30 at 5:40 PM |
| Options Traders Expect Huge Moves in Rigel Pharmaceuticals (RIGL) Stock
finance.yahoo.com - March 27 at 9:50 AM |
| Rigel Pharmaceuticals (RIGL) Upgraded at ValuEngine
www.americanbankingnews.com - March 25 at 11:20 AM |
| Rigel Pharmaceuticals, Inc. (RIGL) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 21 at 12:32 PM |
Rigel Pharmaceuticals (NASDAQ:RIGL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Rigel Pharmaceuticals (NASDAQ:RIGL) Income Statement, Balance Sheet and Cash Flow Statement
Rigel Pharmaceuticals (NASDAQ RIGL) Stock Chart for Thursday, April, 19, 2018
Loading chart…
